In This Story
Rafael Holdings, Inc. has submitted its 10-K filing for the fiscal year ended July 31, 2024.
The filing outlines the company's interests in clinical and early-stage pharmaceutical companies, including Cyclo Therapeutics (CYTH-1.19%), LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., and Cornerstone Pharmaceuticals, Inc. Rafael Holdings also holds interests in Rafael Medical Devices, LLC and Day Three Labs, Inc.
Rafael Holdings reported a significant focus on its investment in Cyclo Therapeutics, which is developing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. The company plans to fund the Phase III clinical trial for Trappsol® Cyclo™.
The company holds a majority interest in LipoMedix, which is developing Promitil® as a cancer therapy. LipoMedix has completed several clinical studies and is currently conducting trials in Israel.
Rafael Holdings' subsidiary, Barer Institute, focuses on cancer metabolism research. The company has sought partners for its programs and has entered into a license agreement for one of its technologies.
The company owns a 67% stake in Cornerstone, which is developing CPI-613® (devimistat) for cancer treatment. Cornerstone is also exploring the development of telaglenastat in different indications.
Rafael Medical Devices is developing surgical devices for the orthopedic market, while Day Three Labs focuses on increasing the bioavailability of cannabinoids for third-party manufacturers.
The company previously owned real estate assets, including the 520 Broad Street property in Newark, New Jersey, which was sold in August 2022. Rafael Holdings retains a portion of a commercial building in Jerusalem, Israel.
The report details various risks, including the company's limited resources, competition, reliance on third parties, and potential challenges in obtaining regulatory approvals for its product candidates.
Rafael Holdings emphasizes its strategy to expand its investment portfolio through strategic investments and partnerships, particularly in therapeutics addressing high unmet medical needs.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Rafael Holdings Inc. Class B annual 10-K report dated November 7, 2024. To report an error, please email earnings@qz.com.